Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors
Pediatric Blood & Cancer2006Vol. 47(6), pp. 795–800
Citations Over TimeTop 11% of 2006 papers
Abstract
TOPO/CYC is active in relapsed ETs and warrants further evaluation.
Related Papers
- → Review role of topotecan in gynaecological cancers: Current indications and perspectives(2009)62 cited
- → Clinical experience with topotecan in relapsed ovarian cancer(2003)21 cited
- In vivo potentiation of radiation response by topotecan in human rhabdomyosarcoma xenografted into nude mice.(2000)
- → Topoisomerase I levels in white blood cells of patients with ovarian cancer treated with paclitaxel–cisplatin–topotecan in a phase I study(2002)6 cited
- The role of topotecan as second-line chemotherapy in patients with recurrent epithelial ovarian cancer(2005)